Camrelizumab (SHR-1210) is a мощный humanied high-affinity IgG4-κ моноклональный антитело (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the связывание interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al.
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.